Page last updated: 2024-11-05

zonisamide and Parkinson Disease, Secondary

zonisamide has been researched along with Parkinson Disease, Secondary in 2 studies

Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Tohge, R1
Kaneko, S1
Morise, S1
Oki, M1
Takenouchi, N1
Murakami, A1
Nakamura, M1
Kusaka, H1
Yakushiji, Y1
Ueda, Y1
Tokashiki, S1
Kanemaru, A1
Kojima, T1

Other Studies

2 other studies available for zonisamide and Parkinson Disease, Secondary

ArticleYear
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
    Neuropharmacology, 2021, 10-15, Volume: 198

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic N

2021
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
    Biochemical and biophysical research communications, 2012, Nov-23, Volume: 428, Issue:3

    Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therap

2012